Evaluating the safety and efficacy of the leukotriene receptor antagonist montelukast as adjuvant therapy in obese patients with type 2 diabetes mellitus: A double-blind, randomized, placebo-controlled trial

Evaluating the safety and efficacy of the leukotriene receptor antagonist montelukast as adjuvant therapy in obese patients with type 2 diabetes mellitus: A double-blind, randomized, placebo-controlled trial

Background: Type 2 diabetes mellitus (T2DM) is common with obesity. Metformin is a first-line therapy for this condition. However, it has only a minor impact on weight loss in some patients.Aim: This study aimed to evaluate the effectiveness, tolerability, and safety of combining montelukast therapy...

Full description

Bibliographic Details
Main Authors: Eman El-Khateeb, Eman I. El-Berri, Esraa M. Mosalam, Mohamed Z. Nooh, Shimaa Abdelsattar, Amira M. Alghamdi, Sarah Alrubia, Mahmoud S. Abdallah
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-04-01
Series:Frontiers in Pharmacology
Subjects:
montelukast
T2DM
obesity
leukotriene receptor antagonist
metformin
diabetes
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2023.1153653/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2023.1153653/full

Similar Items